
    
      411 Tanzanian infants were randomly assigned to receive weekly malaria prophylaxis with
      Deltaprimâ„¢ (3.125 mg pyrimethamine plus 25 mg dapsone) or placebo from ages 2-12 months.
      Children were followed-up until age 4 years. Uncomplicated febrile malaria, severe malaria
      and anaemia morbidity were assessed through hospital-based passive surveillance.
    
  